<DOC>
	<DOCNO>NCT01955980</DOCNO>
	<brief_summary>The study create data selection clinically relevant endpoint ass potential Buparid/PARI SINUS postpone sinus surgery patient chronic Rhinosinusitis .</brief_summary>
	<brief_title>Buparid/PARI SINUS Versus Budes® Nasal Spray Therapy Chronic Rhinosinusitis</brief_title>
	<detailed_description />
	<mesh_term>Sinusitis</mesh_term>
	<mesh_term>Budesonide</mesh_term>
	<criteria>Patient confirm diagnosis chronic rhinosinusitis Patient without alternative sinus surgery Patient 's write informed consent obtain prior screen studyspecific procedure Male female , ≥ 18 year age Patient able undergo nasal therapy without restriction Capable correctly use PARI SINUS device Capable understand purpose risk clinical trial Female patient childbearing potential must negative urine pregnancy test prior first IMP administration . Patient able participate study accord Investigator 's opinion Patients cystic fibrosis Patients polyposis nasi grade IIV Patients prior FESS ( Functional Endoscopic Sinus Surgery ) Pregnant breastfeed woman Any active invasive bacterial , viral fungal infection within one week prior first investigational medicinal product ( IMP ) administration No clinically relevant abnormal parameter vital sign , blood biochemistry renal/hepatic function Unlikely comply visit , inhalation procedure measurement schedule protocol Receipt investigational drug part clinical trial within 4 week prior first administration IMP Any coexist medical condition Investigator 's judgement substantially increase risk associate patient 's participation clinical trial Psychiatric disorder alter mental status preclude understand informed consent process and/or completion necessary procedure Drug alcohol abuse Endstage malignancy Known hypersensitivity Budesonide Patients oral steroid therapy within last 3 month Patients need &gt; 1 mg/day Budesonide ( steroidal equivalent ) therapy asthma Patients therapy leukotrienereceptor antagonist , decongestant , antihistamine antibiotic Patients frequent epistaxis ( &gt; 1 episode per week )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>CRS</keyword>
	<keyword>without polyposis</keyword>
</DOC>